What is the management and treatment of G6PD (Glucose-6-Phosphate Dehydrogenase) deficiency in children?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 29, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Management and Treatment of G6PD Deficiency in Children

The management of G6PD deficiency in children primarily involves preventing hemolytic crises by avoiding known triggers, monitoring for signs of hemolysis, and providing supportive care when hemolysis occurs. 1, 2

Understanding G6PD Deficiency

  • G6PD deficiency is the most common enzymatic disorder of red blood cells worldwide, affecting approximately 400 million people 3
  • The severity varies based on genetic variant, with the Mediterranean variant (Gdmed) typically causing more severe reactions than the African variant (GdA-) 4, 1
  • The condition is most prevalent in Africa, southern Europe, the Middle East, Southeast Asia, and Pacific islands, but has now become a worldwide disease 3

Prevention of Hemolytic Crises

Medications to Avoid

  • Seven medications are definitively contraindicated in G6PD deficiency: 5, 1
    • Dapsone
    • Methylthioninium chloride (methylene blue)
    • Primaquine
    • Rasburicase
    • Nitrofurantoin
    • Phenazopyridine
    • Certain "pain killers"

Dietary Triggers to Avoid

  • Fava beans are the most common dietary trigger of hemolysis (32.6% of cases) 2
  • Other legumes that may trigger hemolysis include: 2
    • Falafel (19.4%)
    • Chickpeas (10.8%)
    • Broad beans (7.6%)
    • Green peas (4.4%)
    • Peanuts (3.8%)
    • Lentils (2.8%)
    • Black-eyed peas (2%)

Other Triggers

  • Infections can trigger hemolysis (12.4% of cases), including pneumonia, tonsillitis, typhoid fever, hepatitis A, and urinary tract infections 2
  • Traditional medicines containing plants like Acalypha indica should be avoided 6

Screening and Diagnosis

  • Screening is strongly recommended for patients with predisposing racial or ethnic backgrounds (Mediterranean, African, Indian, or Southeast Asian descent) 4, 1
  • Qualitative screening is sufficient for initial assessment, but quantitative testing may be needed to determine the degree of deficiency 1
  • G6PD levels may be falsely elevated during acute hemolysis, so repeat testing after 3 months may be necessary for accurate diagnosis 7

Management of Acute Hemolytic Crisis

Clinical Presentation

  • Acute hemolysis typically presents with: 2, 6
    • Pallor (100% of cases)
    • Dark red urine (89.6%)
    • Jaundice (87.8%)
    • Symptoms usually appear 24-72 hours after exposure to triggers

Treatment Approach

  • For severe hemolytic anemia (hemoglobin <6 g/dL), hospitalization and blood transfusion may be required 6
  • For neonatal jaundice related to G6PD deficiency: 7, 8
    • Phototherapy is the primary treatment
    • Intervention at lower total serum bilirubin levels is recommended for G6PD-deficient infants
    • Exchange transfusion may be necessary in severe cases, though it carries risks

Monitoring

  • Monitor for signs of hemolysis when starting any new medication, including: 5
    • Jaundice
    • Dark urine
    • Fatigue
    • Pallor

Patient and Family Education

  • Educate patients and families about: 3
    • The nature of G6PD deficiency
    • Medications, foods, and other triggers to avoid
    • Signs and symptoms of hemolytic crisis
    • When to seek medical attention

Special Considerations

  • The highest prevalence of hemolytic crises occurs in children aged 1-3 years (92% of cases) 2
  • Males are more commonly affected than females due to X-linked inheritance pattern 2
  • A recent real-world study found that many medications previously thought to be risky (including ciprofloxacin, sulfamethoxazole, hydroxychloroquine) were prescribed safely to G6PD-deficient patients 9

Follow-up Care

  • Regular follow-up is recommended to monitor for long-term complications and reinforce preventive measures 3
  • Consider genetic counseling for families with G6PD deficiency 8

References

Guideline

Medications Contraindicated in G6PD Deficiency

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Study of Glucose-6-Phosphate Dehydrogenase Deficiency: 5 Years Retrospective Egyptian Study.

Endocrine, metabolic & immune disorders drug targets, 2018

Guideline

Cefuroxime Safety in G6PD Deficiency Patients

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Miralax Safety in G6PD Deficiency

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Glucose-6-phosphate dehydrogenase deficiency. WHO Working Group.

Bulletin of the World Health Organization, 1989

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.